Gilead Sciences Inc. (GILD): Price and Financial Metrics

Gilead Sciences Inc. (GILD): $62.36

0.55 (+0.89%)

POWR Rating

Component Grades













Add GILD to Watchlist
Sign Up

Industry: Biotech



in industry


  • Value is the dimension where GILD ranks best; there it ranks ahead of 99.29% of US stocks.
  • GILD's strongest trending metric is Sentiment; it's been moving down over the last 179 days.
  • GILD ranks lowest in Momentum; there it ranks in the 4th percentile.

GILD Stock Summary

  • GILD has a market capitalization of $75,897,763,404 -- more than approximately 96.5% of US stocks.
  • In terms of twelve month growth in earnings before interest and taxes, Gilead Sciences Inc is reporting a growth rate of 246.22%; that's higher than 91.47% of US stocks.
  • Gilead Sciences Inc's shareholder yield -- a measure of how much capital is returned to stockholders via dividends and buybacks -- is 11.51%, greater than the shareholder yield of 85.92% of stocks in our set.
  • Stocks with similar financial metrics, market capitalization, and price volatility to Gilead Sciences Inc are KLAC, ADI, EW, NTES, and ON.
  • GILD's SEC filings can be seen here. And to visit Gilead Sciences Inc's official web site, go to

GILD Valuation Summary

  • GILD's price/sales ratio is 3.4; this is 10.53% lower than that of the median Healthcare stock.
  • GILD's price/sales ratio has moved down 24.1 over the prior 243 months.
  • Over the past 243 months, GILD's price/sales ratio has gone down 24.1.

Below are key valuation metrics over time for GILD.

Stock Date P/S P/B P/E EV/EBIT
GILD 2021-08-31 3.4 4.6 17.7 15.0
GILD 2021-08-30 3.4 4.6 17.5 14.9
GILD 2021-08-27 3.4 4.5 17.3 14.8
GILD 2021-08-26 3.4 4.5 17.3 14.8
GILD 2021-08-25 3.4 4.5 17.3 14.8
GILD 2021-08-24 3.4 4.6 17.5 14.9

GILD Growth Metrics

    The 4 year net cashflow from operations growth rate now stands at -50.73%.
  • Its 5 year net cashflow from operations growth rate is now at -50.73%.
  • The 2 year cash and equivalents growth rate now stands at 31.51%.
GILD's revenue has moved up $4,985,000,000 over the prior 34 months.

The table below shows GILD's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2021-12-31 27,305 11,384 6,225
2021-09-30 27,482 10,095 7,394
2021-06-30 26,638 9,092 5,162
2021-03-31 25,564 9,342 301
2020-12-31 24,689 8,168 123
2020-09-30 23,147 8,832 1,268

GILD's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • GILD has a Quality Grade of B, ranking ahead of 89.87% of graded US stocks.
  • GILD's asset turnover comes in at 0.406 -- ranking 114th of 682 Pharmaceutical Products stocks.
  • ENTA, RDUS, and ADMS are the stocks whose asset turnover ratios are most correlated with GILD.

The table below shows GILD's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-09-30 0.406 0.805 0.259
2021-06-30 0.402 0.801 0.179
2021-03-31 0.405 0.806 0.066
2020-12-31 0.403 0.815 0.058
2020-09-30 0.389 0.790 0.058
2020-06-30 0.375 0.786 0.009

GILD Price Target

For more insight on analysts targets of GILD, see our GILD price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $75.84 Average Broker Recommendation 1.7 (Moderate Buy)

GILD Stock Price Chart Interactive Chart >

Price chart for GILD

GILD Price/Volume Stats

Current price $62.36 52-week high $74.12
Prev. close $61.81 52-week low $57.17
Day low $61.27 Volume 5,207,600
Day high $62.43 Avg. volume 9,668,519
50-day MA $62.03 Dividend yield 4.68%
200-day MA $65.27 Market Cap 78.22B

Gilead Sciences Inc. (GILD) Company Bio

Gilead Sciences Inc. is a biopharmaceutical company that discovers, develops, and commercializes new medicines in areas of unmet medical need. Its products target a number of areas, such as HIV, liver diseases, cardiovascular and other diseases. Daniel O’Day has been Gilead Science’s Chief Executive Officer since March of 2019 and the company is headquartered in Foster City, California. With over 10,000 employees worldwide, the company has operations in North America, Asia, the Middle East and Europe. As of 2019, the company had global sales of $22.1 billion. Some of Gilead Science’s major competitors are Novo Nordisk A/S ADR (NVO), Biogen Inc. (BIIB), and Novartis AG ADR (NVS).

GILD Latest News Stream

Event/Time News Detail
Loading, please wait...

GILD Latest Social Stream

Loading social stream, please wait...

View Full GILD Social Stream

Latest GILD News From Around the Web

Below are the latest news stories about Gilead Sciences Inc that investors may wish to consider to help them evaluate GILD as an investment opportunity.

3 Moonshot Stocks Insiders Are Buying. What Do They Know?

Biotech stocks aren't a sure thing, but one good sign is insiders buying up shares.

Thomas Yeung on InvestorPlace | February 25, 2022

VIR Q4 Earnings Beat on Higher Revenues From Covid Treatment

VIR beat earnings estimates in the fourth quarter on higher sotrovimab revenues for COVID-19 patients.

Yahoo | February 25, 2022

Gilead Launches Pharmaceutical Education Program to Increase Workplace Diversity (Black Enterprise)

By Derek Major

Yahoo | February 24, 2022

Tesla Is Just One Reason Why Stocks Are Actually 21% Cheaper Now

Curious just how much cheaper the S&P 500 is now due to the sell-off? It's now a nearly a quarter off in about a year's time.

Yahoo | February 23, 2022

Is Moderna the Next Gilead or the Next Regeneron?

MRNA stock is seen purely as a Covid-19 play.

Dana Blankenhorn on InvestorPlace | February 22, 2022

Read More 'GILD' Stories Here

GILD Price Returns

1-mo -0.49%
3-mo 4.07%
6-mo -11.45%
1-year -5.85%
3-year 2.45%
5-year 6.52%
YTD -11.93%
2021 29.95%
2020 -6.70%
2019 7.88%
2018 -9.92%
2017 2.96%

GILD Dividends

Ex-Dividend Date Type Payout Amount Change
Loading, please wait...
View Full GILD Dividend History

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!

Page generated in 0.4873 seconds.